Latest Nucleosides Stories
WELWYN GARDEN CITY, England, May 9, 2011 /PRNewswire/ -- - Best-in-Class Candidate With Potential in Treatment of CNS Diseases Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.
WALTHAM, Mass., April 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Celgene's Vidaza (azacitidine) (seven-day dosing) will retain Decision Resources' proprietary clinical gold standard status through 2013 for the treatment of high-risk myelodysplastic syndromes.
SCHAUMBURG, Ill., Sept. 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of adenosine injection, USP, an antiarrhythmic drug used to treat paroxysmal supraventricular tachycardia.
WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S.
Adenosine Regulation with GP531 Improves the Heart's Pumping Function in Dogs with Advanced Chronic Heart Failure NEW YORK, June 3 /PRNewswire/ -- PeriCor Therapeutics, Inc.
The Need for More-Efficacious Treatments Creates Significant Opportunity for Drug Developers in this Niche Market, According to a New Report from Decision Resources WALTHAM, Mass., May 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2012, growth in the myelodysplastic syndromes drug market will be driven principally by the launch in Europe of Celgene's Vidaza and Revlimid.
VIDAZA Restores Gene Function to Double Survival and Increase Transfusion Independence CROSSWICKS, N.J., Feb.